The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial
Open accessAbstract
Rationale & Objective Epidemiologic and clinical studies have suggested that urate-lowering therapy may slow the progression of chronic kidney disease (CKD). However, definitive evidence is lacking. Study Design Randomized, double-blind, placebo-controlled trial. Setting & Participants 467 patients with stage 3 CKD and asymptomatic hyperuricemia at 55 medical institutions in Japan. Intervention Participants were randomly assigned in a 1:1 ratio to receive febuxostat or placebo for 108 weeks. Outcomes The primary end point was the slope (in mL/min/1.73m 2 per year) of estimated glomerular filtration rate (eGFR). Secondary end points included changes in eGFRs and serum uric acid levels at 24, 48, 72, and 108 weeks of follow-up and the event of doubling of serum creatinine level or initiation of dialysis therapy. Results Of 443 patients who were randomly assigned, 219 and 222 assigned to febuxostat and placebo, respectively, were included in the analysis. There was no significant difference in mean eGFR slope between the febuxostat (0.23±5.26mL/min/1.73m 2 per year) and placebo (−0.47±4.48mL/min/1.73m 2 per year) groups (difference, 0.70; 95% CI, −0.21 to 1.62; P =0.1). Subgroup analysis demonstrated a significant benefit from febuxostat in patients without proteinuria ( P =0.005) and for whom serum creatinine concentration was lower than the median ( P =0.009). The incidence of gouty arthritis was significantly lower ( P =0.007) in the febuxostat group (0.91%) than in the placebo group (5.86%). Adverse events specific to febuxostat were not observed. Limitations GFR was estimated rather than measured, and patients with stages 4 and 5 CKD were excluded. Conclusions Compared to placebo, febuxostat did not mitigate the decline in kidney function among patients with stage 3 CKD and asymptomatic hyperuricemia. Funding Funded by Teijin Pharma Limited. Trial Registration Registered at the UMIN (University Hospital Medical Information Network) Clinical Trials Registry with study number UMIN000008343.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Revised Equations for Estimated GFR From Serum Creatinine in Japan
Matsuo, S., Imai, E., Horio, M., Yasuda, Y., Tomita, K., Nitta, K., Yamagata, K., Tomino, Y., Yokoyama, H., & Hishida, A. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.12.034 · Cited by 6,422
Self-citationUric Acid and Cardiovascular Risk
Feig, D. I., Kang, D.-H., & Johnson, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800885 · Cited by 2,440
A Role for Uric Acid in the Progression of Renal Disease
Kang, D.-H., Nakagawa, T., Feng, L., Watanabe, S., Han, L., Mazzali, M., Truong, L., Harris, R., & Johnson, R. J. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000034910.58454.fd · Cited by 1,304
Feig, D. I., Soletsky, B., & Johnson, R. J. (2008) · JAMA · doi:10.1001/jama.300.8.924 · Cited by 914
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
White, W. B., Saag, K. G., Becker, M. A., Borer, J. S., Gorelick, P. B., Whelton, A., Hunt, B., Castillo, M., & Gunawardhana, L. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1710895 · Cited by 909
Siu, Y.-P., Leung, K.-T., Tong, M. K.-H., & Kwan, T.-H. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.10.006 · Cited by 834
Effect of Allopurinol in Chronic Kidney Disease Progression and Cardiovascular Risk
Goicoechea, M., de Vinuesa, S. G., Verdalles, U., Ruiz-Caro, C., Ampuero, J., Rincón, A., Arroyo, D., & Luño, J. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01580210 · Cited by 834
Hyperuricemia and incident hypertension: A systematic review and meta‐analysis
Grayson, P. C., Kim, S. Y., LaValley, M., & Choi, H. K. (2011) · Arthritis Care & Research · doi:10.1002/acr.20344 · Cited by 756
Elevated Uric Acid Increases the Risk for Kidney Disease
Obermayr, R. P., Temml, C., Gutjahr, G., Knechtelsdorfer, M., Oberbauer, R., & Klauser-Braun, R. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008010080 · Cited by 647
Cited by
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Dalbeth, N., Gosling, A. L., Gaffo, A., & Abhishek, A. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00569-9 · Cited by 1,338
2020 American College of Rheumatology Guideline for the Management of Gout
FitzGerald, J. D., Dalbeth, N., Mikuls, T., Brignardello‐Petersen, R., Guyatt, G., Abeles, A. M., Gelber, A. C., Harrold, L. R., Khanna, D., King, C., et al. (2020) · Arthritis Care & Research · doi:10.1002/acr.24180 · Cited by 983
2020 American College of Rheumatology Guideline for the Management of Gout
FitzGerald, J. D., Dalbeth, N., Mikuls, T., Brignardello‐Petersen, R., Guyatt, G., Abeles, A. M., Gelber, A. C., Harrold, L. R., Khanna, D., King, C., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41247 · Cited by 810
Dalbeth, N., Choi, H. K., Joosten, L. A. B., Khanna, P. P., Matsuo, H., Perez-Ruiz, F., & Stamp, L. K. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0115-y · Cited by 693
Hyperuricemia and its related diseases: mechanisms and advances in therapy
Du, L., Zong, Y., Li, H., Wang, Q., Xie, L., Yang, B., Pang, Y., Zhang, C., Zhong, Z., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01916-y · Cited by 631
Yanai, H., Adachi, H., Hakoshima, M., & Katsuyama, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179221 · Cited by 595
Effects of Allopurinol on the Progression of Chronic Kidney Disease
Badve, S. V., Pascoe, E. M., Tiku, A., Boudville, N., Brown, F. G., Cass, A., Clarke, P., Dalbeth, N., Day, R. O., de Zoysa, J. R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915833 · Cited by 473
Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease
Borghi, C., Agabiti-Rosei, E., Johnson, R. J., Kielstein, J. T., Lurbe, E., Mancia, G., Redon, J., Stack, A. G., & Tsioufis, K. P. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.07.006 · Cited by 435
Uric acid and cardiovascular disease: A clinical review
Saito, Y., Tanaka, A., Node, K., & Kobayashi, Y. (2021) · Journal of Cardiology · doi:10.1016/j.jjcc.2020.12.013 · Cited by 374
New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity
Furuhashi, M. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00378.2020 · Cited by 361
Metadata
- Authors
- Kimura, K., Hosoya, T., Uchida, S., Inaba, M., Makino, H., Maruyama, S., Ito, S., Yamamoto, T., Tomino, Y., Ohno, I., Shibagaki, Y., Iimuro, S., Imai, N., Kuwabara, M., Hayakawa, H., Ohtsu, H., Ohashi, Y., Kimura, K., Hosoya, T., Ito, S., Inaba, M., Tomino, Y., Uchida, S., Makino, H., Matsuo, S., Yamanaka, H., Yamamoto, T., Ohno, I., Shibagaki, Y., Iimuro, S., Imai, N., Kuwabara, M., Hayakawa, H., Akizawa, T., Teramoto, T., Kasanuki, H., Yoshimura, K., Kimura, K., Hosoya, T., Shibagaki, Y., Ohno, I., Sato, H., Uchida, S., Horikoshi, S., Maruyama, S., Inaba, M., Moriwaki, Y., Uchida, H., Kaneshiro, N., Imai, N., Moriya, H., Komatsu, Y., Kaname, S., Hanaoka, K., Ogura, M., Ikeda, M., Kasai, K., Sugiura, A., Takahashi, K., Kojima, K., Nitta, K., Tamai, H., Nagaya, H., Okuno, S., Kakiya, R., Takeoka, H., Hirata, K., Asano, K., Fukaya, Y., Iwaida, Y., Tsuneda, Y., Nishimura, S., Hiramatsu, T., Isaka, Y., Ito, T., Yuzawa, Y., Yamagata, K., Sofue, T., Jinguji, Y., Hirano, K., Matsuyama, K., Mizumoto, T., Shibuya, Y., Sugawara, M., Kadomura, M., Teshima, Y., Ohtani, H., Kamata, H., Okawara, S., Fukushima, M., Takemura, K., Kinugasa, E., Kogure, M., & Ehara, Y.
- Venue
- American Journal of Kidney Diseases
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 72
- Issue
- 6
- Pages
- 798-810
- ISSN
- 0272-6386 (ISSN-L)
- OpenAlex
- W2889116610
- Cited by
- 383
- References
- 36
- FWCI
- 26.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.